BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ventus Therapeutics U.S.\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Ventus Therapeutics U.S.\, Inc.'s
  drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07260877-5644@assetmemo.bio
DTSTAMP:20261121T005950Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:VENT-03: Phase 2 readout est. (NCT07260877)
DESCRIPTION:VENT-03\, phase 2\, Systemic Lupus Erythematosus.\nStudy: A Mul
 ticenter\, Randomized\, Double-Blind\, Placebo-Controlled\, Phase 2a Study
  With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-0
 3 in Adult Participants With Active Cutaneous Lupus Erythematosus With or 
 Without Systemic Lupus Erythematosus\nEstimated primary completion: Decemb
 er 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/vent-03#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07260877
URL:https://assetmemo.bio/drug/vent-03#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
